June 1, 2020 / 11:22 AM / a month ago

BRIEF-Aileron Reports Positive Interim Results From Trial Of ALRN-6924

June 1 (Reuters) - Aileron Therapeutics Inc:

* AILERON THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 1B/2 CLINICAL TRIAL OF ALRN-6924 FOR THE PREVENTION OF TOPOTECAN-INDUCED TOXICITIES DURING TREATMENT FOR SMALL CELL LUNG CANCER

* AILERON THERAPEUTICS INC - OBSERVED A PROTECTIVE EFFECT AGAINST SEVERE CHEMOTHERAPY-INDUCED ANEMIA AND THROMBOCYTOPENIA ACROSS ALL DOSE LEVELS

* AILERON THERAPEUTICS INC - POSITIVE INTERIM DATA FROM OPEN-LABEL PHASE 1B DOSE OPTIMIZATION PART OF ITS ONGOING PHASE 1B/2 CLINICAL TRIAL OF ALRN-6924 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below